Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Inducts advanced AI-Powered 24x7 remote patient monitoring system
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
His resignation would be effective from March 18, 2024
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
The inspection of the facility conducted from August 7 to August 11, 2023
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Subscribe To Our Newsletter & Stay Updated
